Stiefel Laboratories Appoints First Chief Scientific Officer

Stiefel Laboratories, Inc., the world's largest independent pharmaceutical company specializing in dermatology, today announced Gavin Corcoran, M.D., FACP, has been promoted to the newly created position of chief scientific officer.

Creating the position of chief scientific officer will reinforce the already critical role played by the R&D organization and the unity between all R&D departments. It also will further strengthen the collaboration among Stiefel's five R&D facilities around the world.

As chief scientific officer, Corcoran will oversee global scientific and operational activities related to product development and support; medical and scientific affairs; clinical and pre-clinical research; pharmacovigilance; portfolio planning; and regulatory affairs.

"Gavin's promotion to chief scientific officer is a testament to the wonderful work he has done for Stiefel since he came on board," said Brent Stiefel, executive vice president, Global Corporate Development and Product Portfolio. "We chose Gavin to lead our R&D division because his vast experience along with his keen understanding of the industry arms him with the insight that will improve today's skin treatments and develop tomorrow's solutions."

The accomplishments Stiefel references include Corcoran establishing global R&D headquarters in Research Triangle Park, North Carolina; helping to lead integration following the acquisition of Connetics Corporation; overseeing R&D facilities on four continents; and strengthening the alignment of the R&D objectives and structure with the strategic direction of the business.

Prior to his promotion, Corcoran served as senior vice president, Global Research and Development. He joined Stiefel in 2005 as senior vice president, Global Clinical and Regulatory Affairs and has been a driving force in advancing the expansion of a world-class, global research and development organization. With this promotion, Corcoran will remain in Stiefel's R&D headquarters in Research Triangle Park and continue to report to Brent Stiefel.

Corcoran is a physician with specialties in internal medicine and infectious diseases and professional experience in private practice, academia and the pharmaceutical industry. A native of South Africa, he attended medical school at the University of the Witwatersrand in Johannesburg. His extensive pharmaceutical experience includes clinical research and regulatory leadership positions at Bayer, Schering-Plough and Amgen. In addition, he has successfully worked on drug development in a variety of fields, including anti-infectives, diabetes and dermatological infections.

About Stiefel Laboratories, Inc.

Founded in 1847, Stiefel Laboratories (a privately held company) is the world's largest independent pharmaceutical company specializing in dermatology. The company manufactures and markets a variety of prescription and non-prescription dermatological products. Some of the newest and best-known brands include Duac(R) Topical Gel (clindamycin, 1% - benzoyl peroxide, 5%)

Stiefel Laboratories supplements its R&D efforts by seeking strategic partnerships and acquisitions around the world. To learn more about Stiefel Laboratories, Inc. visit www.stiefel.com

SOURCE: Stiefel Laboratories, Inc.

CONTACT: Erin Bacher,

Associate Director,

Global Public Relations,

+1-678-889-4039,

[email protected] , or

Amy Button,

Coordinator,

Global Public Relations,

+1-678-714-4153,

[email protected],

both of Stiefel Laboratories, Inc.

Web site: http://www.stiefel.com

--Distributed by AsiaNet ( www.asianetnews.net )--

• ข่าวStiefel Laboratories
• ข่าวthe collaboration
• ข่าวo:heal
• ข่าวo:asn
• ข่าวo:eco